Cargando…

Critical appraisal of extended-release hydrocodone for chronic pain: patient considerations

Opioid analgesics are currently the most effective pharmacologic option for the management of both acute and chronic forms of moderate-to-severe pain. Although the “as-needed” use of immediate-release formulations is considered optimum for treating acute, painful episodes of limited duration, the sc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gould, Harry J, Paul, Dennis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622415/ https://www.ncbi.nlm.nih.gov/pubmed/26543371 http://dx.doi.org/10.2147/TCRM.S81979

Ejemplares similares

Extended-release hydrocodone – gift or curse?
por: Krashin, Daniel, et al.
Publicado: (2013)

Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain
por: Pergolizzi, Joseph, et al.
Publicado: (2018)

Single- and multiple-dose pharmacokinetics of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) compared with immediate-release hydrocodone bitartrate/ibuprofen and immediate-release tramadol HCl/acetaminophen
por: Devarakonda, Krishna, et al.
Publicado: (2015)

Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers
por: Farr, Stephen J, et al.
Publicado: (2015)

A long-term, open-label safety study of single-entity hydrocodone bitartrate extended release for the treatment of moderate to severe chronic pain
por: Nalamachu, Srinivas, et al.
Publicado: (2014)

Efficacy and tolerability of a hydrocodone extended-release tablet formulated with abuse-deterrence technology for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis or low back pain
por: Hale, Martin E, et al.
Publicado: (2015)

Preclinical and Clinical Pharmacology of Hydrocodone for Chronic Pain: A Mini Review
por: Cardia, Luigi, et al.
Publicado: (2018)

Opioid Treatment Patterns Following Prescription of Immediate-Release Hydrocodone
por: Ben-Joseph, Rami, et al.
Publicado: (2016)

Patterns of abuse and routes of administration for immediate‐release hydrocodone combination products
por: Cassidy, Theresa A., et al.
Publicado: (2017)

Comparison of single-dose and multiple-dose pharmacokinetics between two formulations of hydrocodone bitartrate/acetaminophen: immediate-release versus biphasic immediate-release/extended release
por: Devarakonda, Krishna, et al.
Publicado: (2015)

Assessment of Alcohol-Induced Dose Dumping with a Hydrocodone Bitartrate Extended-Release Tablet Formulated with CIMA(®) Abuse Deterrence Technology
por: Darwish, Mona, et al.
Publicado: (2015)

Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users
por: Harris, Stephen C., et al.
Publicado: (2016)

Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users
por: Harris, Stephen C., et al.
Publicado: (2017)

Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia
por: Hussein, Ayman A, et al.
Publicado: (2010)

Real-world utilization of once-daily extended-release abuse deterrent formulation of hydrocodone: a comparison with the pre-approval randomized clinical trials
por: Taber, Louise, et al.
Publicado: (2017)

Evaluating the stability of opioid efficacy over 12 months in patients with chronic noncancer pain who initially demonstrate benefit from extended release oxycodone or hydrocodone: harmonization of Food and Drug Administration patient-level drug safety study data
por: Farrar, John T., et al.
Publicado: (2022)

Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Darwish, Mona, et al.
Publicado: (2017)

Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Bond, Mary, et al.
Publicado: (2018)

Patient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozin
por: Salvo, Marissa C, et al.
Publicado: (2014)

Tramadol extended-release in the management of chronic pain
por: McCarberg, Bill
Publicado: (2007)

Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations
por: García, Margarita, et al.
Publicado: (2009)

Hydrocodone, Oxycodone, and Morphine Metabolism and Drug–Drug Interactions
por: Coates, Shelby, et al.
Publicado: (2023)

Opioid-related overdose and chronic use following an initial prescription of hydrocodone versus oxycodone
por: Weiner, Scott G., et al.
Publicado: (2022)

Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations
por: Uy, J, et al.
Publicado: (2012)

Multidisciplinary Approach to Treating Chronic Pain in Patients with Ehlers–Danlos Syndrome: Critically Appraised Topic
por: Whalen, Kiley C, et al.
Publicado: (2022)

Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials
por: Devarakonda, Krishna, et al.
Publicado: (2015)

Tapentadol extended-release for treatment of chronic pain: a review
por: Vadivelu, Nalini, et al.
Publicado: (2011)

Exenatide extended-release; clinical trials, patient preference, and economic considerations
por: Doggrell, Sheila A
Publicado: (2013)

Extended-release morphine sulfate in treatment of severe acute and chronic pain
por: Balch, Robert J, et al.
Publicado: (2010)

Quantification of Opioid Prescription Practice Changes Due to Hydrocodone Combination Product Rescheduling in an Academic Pain Clinic
por: Ngo, John, et al.
Publicado: (2020)

Smartphone applications for chronic pain management: a critical appraisal
por: Alexander, John C, et al.
Publicado: (2016)

Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain
por: Pergolizzi, Joseph V., et al.
Publicado: (2018)

Patient considerations in early management of Parkinson’s disease: focus on extended-release pramipexole
por: Salawu, Fatai Kunle
Publicado: (2012)

Prolonged Ventricular Asystole: A Rare Adverse Effect of Hydrocodone Use
por: Sudhakaran, Sivakumar, et al.
Publicado: (2014)

Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations
por: Kesayan, Tigran, et al.
Publicado: (2015)

OnabotulinumtoxinA for chronic migraine: a critical appraisal
por: Gooriah, Rubesh, et al.
Publicado: (2015)

Development of a New Type of Prolonged Release Hydrocodone Formulation Based on Egalet® ADPREM Technology Using In Vivo–In Vitro Correlation
por: Hemmingsen, Pernille H., et al.
Publicado: (2011)

Developments in managing severe chronic pain: role of oxycodone–naloxone extended release
por: Fanelli, Guido, et al.
Publicado: (2015)

Update and critical appraisal of sevelamer in the management of chronic renal failure
por: Grinfeld, Jacob, et al.
Publicado: (2010)

Tapentadol extended release for the management of chronic neck pain
por: Billeci, Domenico, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4ciqn7ikcrppcufhvdmoan5346